| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/22/2002 | EP1206447A1 Selective inhibitors of the urokinase plasminogene activators |
| 05/22/2002 | EP1206444A1 Compounds that inhibit tryptase activity |
| 05/22/2002 | EP1206442A1 Substituted chiral allosteric hemoglobin modifiers |
| 05/22/2002 | EP1206429A2 Stilbenes with vascular damaging activity |
| 05/22/2002 | EP1206285A2 Drug-carrier complexes and methods of use thereof |
| 05/22/2002 | EP1206277A1 Methods and materials for the treatment of prostatic carcinoma |
| 05/22/2002 | EP1206274A2 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/22/2002 | EP1206267A1 Medicaments that contain xenogenic oligo- or/and polyribonucleotides |
| 05/22/2002 | EP1206266A2 Formulations for parenteral use of estramustine phosphate and albumin |
| 05/22/2002 | EP1206259A2 Use of substance p antagonists for the treatment of adenocarcinoma |
| 05/22/2002 | EP1206257A1 Use of amino acids for making medicines for treating to insulin-resistance |
| 05/22/2002 | EP1206256A2 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 05/22/2002 | EP1206254A1 Drug releasing biodegradable fiber implant |
| 05/22/2002 | EP1206252A1 Amplification of folate-mediated targeting to tumor cells using polymers |
| 05/22/2002 | EP1206251A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles |
| 05/22/2002 | EP1206234A2 Methods and compositions for modulating cell proliferation and cell death |
| 05/22/2002 | EP1206233A2 Serine proteases |
| 05/22/2002 | EP1147107A4 Novel angiogenesis inhibitors |
| 05/22/2002 | EP0981648A4 ANTISENSE INHIBITION OF ras GENE WITH CHIMERIC AND ALTERNATING OLIGONUCLEOTIDES |
| 05/22/2002 | EP0902681B1 Inhibition of selectin binding |
| 05/22/2002 | EP0894093B1 Soluble tachykinin antagonists, the preparation and use thereof |
| 05/22/2002 | EP0888349B1 Pyrrolopyrimidines and processes for their preparation |
| 05/22/2002 | EP0745085B1 Texaphyrin metal complexes having improved functionalization |
| 05/22/2002 | EP0681575B1 Process for the preparation of Baccatin III analogs bearing new C2 and C4 functional groups |
| 05/22/2002 | CN1350545A Spray drying of thrombin inhibitors |
| 05/22/2002 | CN1350542A Xylo-LNA analogues |
| 05/22/2002 | CN1350540A Process for preparing amine platinum complexes |
| 05/22/2002 | CN1350539A Imidazo-containing heterocyclic compounds, their compositions and uses |
| 05/22/2002 | CN1350537A Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 05/22/2002 | CN1350534A Substituted bicyclic heteroaryl compounds as integrin antagonists |
| 05/22/2002 | CN1350533A New ECE inhibitors, their production and their use |
| 05/22/2002 | CN1350528A 4,5,6,7-tetrahydroindazole derivatives as antitumor agents |
| 05/22/2002 | CN1350524A Quinoline derivatives as inhibitors of MEK enzymes |
| 05/22/2002 | CN1350523A Indoline derivatives as progesterohe antagonists |
| 05/22/2002 | CN1350464A Docetaxel in combination with rhumab HER2 for the treatment of cancers |
| 05/22/2002 | CN1350458A Protease inhibitors |
| 05/22/2002 | CN1349983A Non-peptide neomatal vascularization inhibitor |
| 05/22/2002 | CN1349965A Fatty amido substituted desmethoxy hypocrellin with fatty ring or aromatic ring and its synthesis and application |
| 05/22/2002 | CN1349827A Human tumor necrosis factor-alpha oral prepn. of marine polychlorella |
| 05/22/2002 | CN1349825A Compound Chinese medicine prepn. containing Jisongrong and Its prepn process |
| 05/22/2002 | CN1349808A Externally applied cancer treating foamed ointment |
| 05/22/2002 | CN1085212C Rapamycin 42-oximes and hydroxylamines |
| 05/22/2002 | CN1085211C Synthetic metal-substituted bacteriochlorophyll derivatives and use thereof |
| 05/22/2002 | CN1085205C Bicyclic amino acids |
| 05/21/2002 | US6392071 Anticancer agents |
| 05/21/2002 | US6392063 Hydrolysis-promoting hydrophobic taxane derivatives |
| 05/21/2002 | US6392055 Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin A |
| 05/21/2002 | US6392053 Process for preparing arylacetylaminothiazoles |
| 05/21/2002 | US6392028 Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| 05/21/2002 | US6392016 Preferential polypeptide for use in the diagnosis and treatment of tumors; antiproliferative agents |
| 05/21/2002 | US6391907 Anticancer agents; contraceptives |
| 05/21/2002 | US6391904 Bone disorders |
| 05/21/2002 | US6391900 Antitumor agents |
| 05/21/2002 | US6391894 Myt1 kinase inhibitors |
| 05/21/2002 | US6391893 Anticancer agents |
| 05/21/2002 | US6391892 Naphthyl pharmaceutical compounds |
| 05/21/2002 | US6391888 Topical anesthetics useful for treating cancer |
| 05/21/2002 | US6391874 Anticarcinogenic agents; skin disorders |
| 05/21/2002 | US6391850 Methods and compositions for inhibiting angiogenesis |
| 05/21/2002 | US6391848 Soybean protein nutraceuticals |
| 05/21/2002 | US6391832 Medical emulsion for lubrication and delivery of drugs |
| 05/21/2002 | US6391615 Isolate of Antrodia camphorata process for producing a culture of the same and product obtained thereby |
| 05/21/2002 | US6391606 Peptides; for use in the develoment of human diagnostic and therapeutic agents |
| 05/21/2002 | US6391580 Ras proteins |
| 05/21/2002 | US6391579 Nucleotide sequences coding transport protein for use in the treatment of thyroid defects |
| 05/21/2002 | US6391574 AFC1 and RCE1: isoprenylated CAAX processing enzymes |
| 05/21/2002 | US6391543 Screening sample for preferential nucleotide sequences; incubate sample with nucleotide sequences, monitor sample for signal indicating bound nucleotide sequences |
| 05/21/2002 | US6391307 Composition comprising the lower, no-branch culm portion of bamboo |
| 05/21/2002 | US6391306 Treatment of infectious diseases with hsp90-peptide complexes |
| 05/21/2002 | US6391301 Agent for identifying and treating metastasizing tumors |
| 05/21/2002 | US6390821 Phosphorylation |
| 05/20/2002 | WO2002039947A2 Carrier vectors through an epithelium with tight junctions |
| 05/16/2002 | WO2002039121A2 Methods for detecting the efficacy of anticancer treatments |
| 05/16/2002 | WO2002039117A1 Methods for the treatment of cellular proliferative disorders |
| 05/16/2002 | WO2002038803A2 Novel marker for the diagnosis and therapy of tumours |
| 05/16/2002 | WO2002038778A1 Differentiation-inducing substances |
| 05/16/2002 | WO2002038744A2 Proteases |
| 05/16/2002 | WO2002038607A2 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | WO2002038604A1 A new polypeptide-cicliary rootlet protein 45.98 and the polynucleotide encoding it |
| 05/16/2002 | WO2002038579A1 Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging |
| 05/16/2002 | WO2002038575A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase |
| 05/16/2002 | WO2002038563A2 Condensed pyrazindione derivatives as pde inhibitors |
| 05/16/2002 | WO2002038561A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 05/16/2002 | WO2002038541A1 Cyanopyrrolidine derivatives |
| 05/16/2002 | WO2002038186A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | WO2002038177A2 Adjuvant combination formulations |
| 05/16/2002 | WO2002038172A2 Sdf-1 beta expressing tumor cells as tumor vaccines |
| 05/16/2002 | WO2002038169A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | WO2002038168A2 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 05/16/2002 | WO2002038164A1 Combination preparation of a biological response modifier and an anticancer agent and uses thereof |
| 05/16/2002 | WO2002038148A1 ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING φ-HYDROXYFATTY ACIDS |
| 05/16/2002 | WO2002038143A2 Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation |
| 05/16/2002 | WO2002038140A2 Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| 05/16/2002 | WO2002038106A2 Calcilytic compounds |
| 05/16/2002 | WO2002038105A2 Novel polyamine analog-amino acid conjugates useful as anticancer agents |
| 05/16/2002 | WO2002026727A3 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 05/16/2002 | WO2002023784A3 Cysteine protease inhibitors |
| 05/16/2002 | WO2002022000A3 Targeted alpha particle therapy using actinium-225 conjugates |
| 05/16/2002 | WO2002018448A3 Percarboxylated polysaccharides, and a process for their preparation |
| 05/16/2002 | WO2002017892A3 Water-dispersible encapsulated sterols |